Lin Zhao

Prof. Lin Zhao

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
XDXiangying Deng
Xiangying Deng
YGYajun Gui
Yajun Gui
LZLin Zhao
Lin Zhao
Microplastics, as an emerging environmental pollutant, have received widespread attention for their potential impact on ecosystems and human health. Microplastics are defined as plastic particles less than 5 millimeters in diameter and can be categorized as primary and secondary microplastics. Primary microplastics usually originate directly from industrial production, while secondary microplastics are formed by the degradation of larger plastic items. Microplastics are capable of triggering cytotoxicity and chronic inflammation, and may promote cancer through mechanisms such as pro-inflammatory responses, oxidative stress and endocrine disruption. In addition, improved microplastics bring new perspectives to cancer therapy, and studies of microplastics as drug carriers are underway, showing potential for high targeting and bioavailability. Although current studies suggest an association between microplastics and certain cancers (e.g., lung, liver, and breast cancers), the long-term effects and specific mechanisms still need to be studied. This review aimed at exploring the carcinogenicity of microplastics and their promising applications in cancer therapy provides important directions for future research and emphasizes the need for multidisciplinary collaboration to address this global health challenge.

10 October 2025 in Materials Today Bio
Verified
Journal Article
Open access
XDXiangying Deng
Xiangying Deng
XLXinglong Liu
Xinglong Liu
LZLin Zhao
Lin Zhao
Tumor heterogeneity and therapeutic resistance remain formidable obstacles to effective cancer treatment. Remodeling the tumor microenvironment (TME)—which is characterized by hypoxia, acidosis, immunosuppression, and extracellular matrix (ECM) remodeling—has emerged as a promising strategy to overcome these barriers. In recent years, nanotechnology has enabled the development of multifunctional and stimuli-responsive platforms for targeted TME modulation. Inorganic, organic, and hybrid nanocarriers leverage enhanced permeability and retention (EPR) effects, surface ligand engineering, and responsive elements to achieve spatiotemporally controlled drug and gene delivery. These advanced nanoplatforms can simultaneously normalize tumor vasculature, reverse hypoxia, modulate immune suppression, and degrade the ECM, thereby sensitizing tumors to conventional and emerging therapies. Integrating these TME-oriented strategies with photothermal and photodynamic therapy, immunotherapy, and metabolic reprogramming allows the construction of comprehensive, multimodal treatment systems. Furthermore, the convergence of intelligent nanomaterials and artificial intelligence (AI)-guided precision delivery is fostering the concept of therapeutic ecosystems, which enable dynamic treatment feedback and personalized tumor management. This review systematically summarizes the recent progress in nanotechnology-driven TME remodeling, highlights representative mechanisms and design strategies for multifunctional nanoplatforms, and discusses future opportunities and challenges in the development of intelligent, patient-centric cancer therapy systems.

9 July 2024 in Experimental Cell Research
Verified
Journal Article
Closed access
YGYajun Gui
Yajun Gui
XDXiangying Deng
Xiangying Deng
NLNamei Li
Namei Li
LZLin Zhao
Lin Zhao

7 January 2025 in International Journal of Surgery
Verified
Journal Article
Open access
LZLin Zhao
Lin Zhao
YGYajun Gui
Yajun Gui
XDXiangying Deng
Xiangying Deng
The immune response is modulated by a diverse array of signals within the tissue microenvironment, encompassing biochemical factors, mechanical forces, and pressures from adjacent tissues. Furthermore, the extracellular matrix and its constituents significantly influence the function of immune cells. In the case of carcinogenesis, changes in the biophysical properties of tissues can impact the mechanical signals received by immune cells, and these signals can be translated into biochemical signals through mechano-transduction pathways. These mechano-transduction pathways have a profound impact on cellular functions, influencing processes such as cell activation, metabolism, proliferation, and migration etc. The tissue mechanics may undergo temporal changes during the process of carcinogenesis, offering the potential for novel dynamic levels of immune regulation. Here, we review advances in mechanoimmunology in malignancy studies, focusing on how mechanosignals modulate the behaviors of immune cells at the tissue level, thereby triggering an immune response that ultimately influences the development and progression of malignant tumors. Additionally, we have also focused on the development of mechano-immunoengineering systems, with the help of which could help to further understand the response of tumor cells or immune cells to alterations in the microenvironment and may provide new research directions for overcoming immunotherapeutic resistance of malignant tumors.

21 May 2025 in Materials Today Bio
Verified
Journal Article
Open access
HCHai-peng Cheng
Hai-peng Cheng
LZLin Zhao
Lin Zhao
JCJing Cai
Jing Cai
Cuproptosis, a novel copper-dependent regulated cell death mechanism, represents a paradigm shift in oncology by exploiting unique copper dyshomeostasis mechanisms to combat intractable malignancies. While cuproptosis-based therapies hold transformative potential for diverse cancers, their clinical translation is hindered by inherent limitations, including suboptimal immunostimulatory efficacy, insufficient tumor specificity, and immunosuppressive crosstalk within the tumor microenvironment. Recent breakthroughs in nanotechnology have unlocked revolutionary strategies to address these challenges, with copper-based nanotherapeutic systems emerging as precision tools to amplify cuproptosis efficacy. Engineered nanosystems circumvent critical barriers of conventional small-molecule drugs, such as off-target toxicity and pharmacokinetic instability, by enabling spatiotemporal control of copper delivery, microenvironment remodeling, and synergistic activation of cell death cascades. This review systematically examines cutting-edge advances in nanomaterial design for potentiating cuproptosis, emphasizing three transformative frontiers: (1) combinatorial cell death modalities integrating cuproptosis with apoptosis, ferroptosis, or pyroptosis for amplified therapeutic cascades; (2) multimodal nanoplatforms coupling cuproptosis inducers with various treatment modalities to overcome resistance; and (3) precision-targeted delivery systems utilizing ligand/receptor engineering and stimuli-responsive materials for tumor-selective copper overload. Finally, further mechanistic insights into nanomaterial-triggered cuproptosis and its immunomodulatory consequences within tumor niches are critically evaluated.

28 December 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MOMin Ouyang
Min Ouyang
YGYajun Gui
Yajun Gui
NLNamei Li
Namei Li
LZLin Zhao
Lin Zhao
Triple-negative breast cancer (TNBC) is an aggressive disease with a poor prognosis and lack of effective treatment. In this study, TNBCs were analyzed from the perspective of tumor stemness based on scRNA-seq data. The analysis showed that tumor cells of TNBC were divided into 4 subtypes, with subtype 2 having the highest stemness score. A prognostic model of 7 tumor stemness-related genes (AP2S1, CHML, FABP7, FADS2, PAXX, SDC1 and TOP2A) was developed based on marker genes of this subtype and TCGA data, and the predictive power of this feature was well validated in different clinical subgroups. TNBC patients in the low TS group had a better prognosis. In addition, drug sensitivity analysis showed that patients in the high TS (tumor stemness) score group were more sensitive to PD-L1 inhibitors and the chemotherapeutic agents. In conclusion, our study developed a prognostic model based on TNBC tumor stemness cell marker genes, which has a good ability to predict the prognosis of TNBC patients and the effect of response to drug therapy.